LivingGLP1
Study S001858

Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients

ClinicalTrials.gov record

Registration

Registration
NCT05147896
Acronym
SAMAS
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
TRIPLE
Status
UNKNOWN
Enrollment
100
Start
2022-05-01
Primary completion
2023-05-01
Lead sponsor
University Medical Centre Ljubljana
Conditions
Diabetes Mellitus, Type 2; Atherosclerosis
Interventions
DRUG:Semaglutide Oral Tablet
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Change in morphological arterial wall characteristics [1 year]
  • Change in functional arterial wall characteristics [1 year]
  • Change in structural arterial wall characteristics [1 year]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0022434Effect of Oral Semaglutide on Cardiovascular Parameters and Their Mechanisms in Patients with Type 2 Diabetes: Rationale and Design of the Semaglutide Anti-Atherosclerotic Mechanisms of Action Study (SAMAS).
Janić M, Diabetes therapy : research, treatment and education of diabetes and related disorders
2022ProtocolPMID 35258841DOIcites ClinicalTrials.gov:NCT05147896; registry reference DERIVED:35258841